College of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China.
College of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China; State Key Laboratory of New-tech for Chinese Medicine Pharmaceutical Process, Jiangsu Kanion Pharmaceutical Co., Ltd, Lianyungang 222047, People's Republic of China; Local Joint Engineering Research Center on the Intelligent Manufacturing of TCM, Jiangsu Kanion Pharmaceutical Co., Ltd, Lianyungang 222047, People's Republic of China.
J Pharm Biomed Anal. 2023 Apr 1;227:115286. doi: 10.1016/j.jpba.2023.115286. Epub 2023 Feb 13.
Shen-Wu-Yi-Shen tablet (SWYST), a well-known traditional Chinese medicine prescription (TCMP), has been effectively used for treating chronic kidney disease (CKD) in clinically. However, an in-depth study of in vivo metabolism of SWYST is lacking. In this study, a targeted and non-targeted strategy based on ultra-performance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry (UPLC-Q-TOF-MS/MS) was developed to screen and characterize SWYST-related xenobiotics in rats. Based on the in-house library, a chemical database of SWYST including 215 constituents was constructed through "find by formula" and further verified by characteristic fragmentations or the literatures. Then the constructed chemical database was applied for the targeted screening of prototypes. As for metabolites, the non-targeted screening was achieved combined the peak picking using the function "find by auto-MS/MS" and peak filtration of the prototypes and endogenous components, while the targeted screening was performed using Metabolite ID according to the possible metabolic reactions. Furthermore, the potential metabolites were preliminarily identified by comparison of the parent compounds or references to the literatures. As a result, 201 exogenous components (87 prototypes and 121 metabolites) were characterized in rats after administration of SWYST, including 55 (17 prototypes and 38 metabolites) in plasma, 151 (52 prototypes and 99 metabolites) in urine, and 121 (74 prototypes and 47 metabolites) in feces. Finally, their possible metabolic pathways were summarized, and the metabolic reactions mainly involved phase I reactions (hydroxylation, deoxygenation, hydrogenation, methylation, oxidation, hydrolysis and esterification) and phase II reactions (glucuronidation and sulfation). The findings of this research reveal the potential active ingredients of SWYST, providing an important material basis for the pharmacokinetics and pharmacodynamics of SWYST.
参乌益肾片(SWYST)是一种著名的中药方剂(TCMP),临床上已有效用于治疗慢性肾脏病(CKD)。然而,体内代谢的深入研究尚缺乏。在这项研究中,开发了一种基于超高效液相色谱-串联四极杆飞行时间质谱(UPLC-Q-TOF-MS/MS)的靶向和非靶向策略,用于筛选和鉴定大鼠体内 SWYST 相关的外来化合物。基于内部库,通过“公式查找”构建了一个包括 215 个成分的 SWYST 化学数据库,并通过特征碎片或文献进一步验证。然后,将构建的化学数据库应用于原型的靶向筛选。对于代谢产物,通过使用“自动-MS/MS 查找”功能进行峰选择,结合原型和内源性成分的峰过滤,实现非靶向筛选,而靶向筛选则通过代谢物 ID 根据可能的代谢反应进行。此外,通过与母体化合物或文献的比较,初步鉴定了潜在的代谢产物。结果,在大鼠给予 SWYST 后,共鉴定出 201 种外源性成分(87 种原型和 121 种代谢产物),包括血浆中的 55 种(17 种原型和 38 种代谢产物)、尿液中的 151 种(52 种原型和 99 种代谢产物)和粪便中的 121 种(74 种原型和 47 种代谢产物)。最后,总结了它们可能的代谢途径,代谢反应主要涉及 I 相反应(羟化、脱氧、加氢、甲基化、氧化、水解和酯化)和 II 相反应(葡萄糖醛酸化和硫酸化)。这项研究的结果揭示了 SWYST 的潜在活性成分,为 SWYST 的药代动力学和药效学提供了重要的物质基础。